El interés en corto de Jin Medical International da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Jin Medical International. Los datos de interés en corto se actualizan cada dos semanas.

Jin Medical International (NASDAQ:ZJYL) Bolsa, Informe de interés en corto

Jin Medical International

Jin Medical International Ltd offers rehabilitation equipment. It is primarily engaged in the design, development, manufacturing, and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's products are sold to distributors in both China and in overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, nursing products, and conlo products.

JIN MEDICAL INTERNATIONAL LTD. - Ordinary Shares

Jin Medical International Ltd

Canaccord Genuity analyst Whitney Ijem maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy and maintains $39 price target.

News

Price Target

Analyst Ratings

RCKT

Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Maintains $39 Price Target

The Company intends to use the net proceeds from this offering, together with proceeds from the expected issuance of up to $650 million aggregate principal amount of new senior secured notes, borrowings under our revolving credit facility and cash on hand, to fund the consideration payable by us in the previously-announced, pending acquisition of all of the equity interests in Guardian Pipeline, L.L.C., Midwestern Gas Transmission Company and Viking Gas Transmission Company from ONEOK Partners Intermediate Limited Partnership and Border Midwestern Company.

Offerings

ZTO DT Midstream Commences Public Offering Of $300M Of Shares Of Common Stock

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and maintains $90 price target.

NTLA

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $90 Price Target

President-elect Donald Trump on Tuesday said he will nominate celebrity physician Dr. Mehmet Oz to lead the Centers for <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Medicare and Medicaid Services (CMS). </a>
The Details: Trump announced Dr. Oz as his pick for CMS administrator in a statement Tuesday afternoon.&nbsp;
"Our broken Healthcare System harms everyday Americans, and crushes our country's budget," Trump said.&nbsp;
"Dr. Oz will be a leader in incentivizing disease prevention, so we get the best results in the world for every dollar we spend on health care in our Great Country," Trump said. "He will also cut waste and fraud within our country's most expensive government agency, which is a third of our nation's health care spend, and a quarter of our entire national budget."
Read More: <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a>
Dr. Oz has a history of offering unproven medical advice and has said his goal was to "empower" Americans to take control of their health, according to the New York Times. He <a href="https://www.nytimes.com/2021/12/26/us/politics/dr-oz-medical-advice.html">promoted the use</a> of hydroxychloroquine as an effective treatment against COVID-19 in the early days of the pandemic, before reversing course and advising patients to wait for evidence from randomized trials.&nbsp;
CMS, an agency within the Health and Human Services Department (HHS), oversees several major health care programs including Medicare, Medicaid, the Children's Health Insurance Program and the Healthcare.gov insurance marketplace exchange. Federal spending on the four programs is $1.6 trillion, or nearly 25% of the entire federal budget.
Last week, Trump announced his intention to nominate another <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">controversial figure,</a> Robert Kennedy Jr., to head the HHS.&nbsp; Other unconventional selections include Trump's choices of former Rep. Matt Gaetz for U.S. attorney general and Fox News host Pete Hegseth for defense secretary.
Chiquita Brooks-LaSure is the current CMS administrator under the Biden administration.&nbsp;
Following Trump&#8217;s announcement, investors may want to monitor shares of UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), the largest Medicare Advantage insurer nationwide, and shares of Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), one of the largest Medicaid insurers.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: G. Holland via Shutterstock

Health Care

Politics

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Trump Picks Dr. Oz As Centers For Medicare And Medicaid Services Administrator

Canaccord Genuity analyst Austin Moeller maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Hold and maintains $76 price target.

ENPH

Canaccord Genuity Maintains Hold on Enphase Energy, Maintains $76 Price Target

The offering consists of $500 million aggregate principal amount of senior secured notes due 2026&nbsp;at a price to the public of 99.948% of their face value and $750&nbsp;million aggregate principal amount of senior secured notes due 2034 at a price to the public of 99.903% of their face value.

Vistra Reveals Pricing Of Private Offering Of $1.25B Of Senior Secured Notes

Canaccord Genuity analyst Sumant Kulkarni maintains Cybin (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#AMEX">CYBN</a>) with a Buy and maintains $86 price target.

CYBN

Canaccord Genuity Maintains Buy on Cybin, Maintains $86 Price Target

Earnings

Advanced Environmental Recycling Technologies

AERT

Aeries Technology Q2 EPS $(0.05), Sales $16.9M Down From $17.6M YoY

Canaccord Genuity analyst Brian McNamara maintains Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) with a Buy and maintains $3 price target.

Canaccord Genuity Maintains Buy on Solo Brands, Maintains $3 Price Target

Solidion Technology Q3 EPS $(0.07), Including Non-Cash Loss On Issuance Of PIPE Common Stock And Warrants

President-elect Donald Trump announced former Congressman Sean Duffy to oversee the Department of Transportation (DOT) on Monday. 
Here's a look at how the latest Trump selection could affect companies in <a href="https://www.benzinga.com/news/24/11/42053292/trump-picks-sean-duffy-as-next-transportation-secretary-says-he-will-usher-in-the-golden-age-of-travel">the transportation sector. </a>
The Details: Duffy, who served in the U.S. House of Representatives from 2011 to 2019, most recently worked as Fox News Media host. He left the position on Monday, according <a href="https://www.nytimes.com/2024/11/18/us/politics/sean-duffy-trump-transportation-dot.html">to</a> the New York Times.
Duffy is the second Fox News employee to be nominated by Trump for a cabinet position. Last week, Trump picked Fox News host Pete Hegseth as Defense Secretary despite <a href="https://www.benzinga.com/news/24/11/41952962/trumps-surprise-defense-secretary-pick-pete-hegseth-jolts-wall-street">lack of government experience</a>.
In 1997, he was a cast member on MTV's "The Real World: Boston.&#8221;
As Transportation Secretary, Duffy would be in charge of major federal agencies, including the Federal Aviation Administration (FAA) and the National Highway Traffic Safety Administration (NHTSA). 
Read More: <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a>
"He will prioritize Excellence, Competence, Competitiveness and Beauty when rebuilding America's highways, tunnels, bridges and airports. He will ensure our ports and dams serve our Economy without compromising our National Security, and he will make our skies safe again by eliminating DEI for pilots and air traffic controllers," Trump said in his announcement.&nbsp;&nbsp;
<h3 class="wp-block-heading">Air Travel</h3>
If approved by the Senate, Duffy can be expected to address ongoing aviation <a href="https://www.benzinga.com/general/travel/24/11/42014904/boeing-begins-layoffs-is-the-737-max-recovery-enough-to-lift-ba-stock">safety issues</a>. This could include matters relating to Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) and air traffic control challenges. As part of Trump's focus on efficiency, Duffy could potentially work to enhance safety measures while streamlining regulations. 
Major airline companies like Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) and American Airlines Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) may be affected by potential policy and regulatory changes, as well. 
<h3 class="wp-block-heading">&#8216;Overall Negative For EV Industry&#8217;</h3>
The DOT also oversees the National Highway Traffic Safety Administration (NHTSA) which is expected to focus on regulatory frameworks for electric vehicles and autonomous driving technologies in the near term.  The NHTSA is likely to establish guidelines for emerging technologies like Tesla, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) autonomous driving software. 
Recent reports suggest Trump has plans to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42046316/trump-set-to-hand-musk-golden-path-for-tesla-after-reversing-course-on-autonomous-vehicle-ban">ease restrictions</a> on self-driving vehicles, which could help companies like Tesla expand FSD and bring robotaxis to the market.
Tesla CEO Elon Musk campaigned heavily for Trump and provided millions to his campaign coffers ahead of Election Day.
At the same time, it seems likely that the incoming Trump administration <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">will eliminate </a>or reduce many of the EV purchase incentives included in the Biden administration&#8217;s Inflation Reduction Act (IRA). 
Wedbush analysts said that Tesla&#8217;s rivals, U.S.-based EV startups like Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) and Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>), could face a major set-back if Trump rolls back current EV tax incentives and rebates, as reports suggest. 
"We believe a Trump presidency would be an overall negative for the EV industry as likely the EV rebates/tax incentives get pulled," Wedbush analysts wrote.&nbsp;
<h3 class="wp-block-heading">Railroads</h3>
If Duffy is confirmed, he will also oversee the Federal Railroad Administration (FRA), which is responsible for safety measures across the rail network. He may address safety concerns following incidents like the East Palestine <a href="https://www.benzinga.com/news/24/04/38240139/norfolk-southern-to-pay-600m-in-ohio-train-derailment-lawsuit">derailment in 2023</a>.
Duffy will also manage billions in federal grants aimed at improving rail infrastructure and upgrading aging rail systems to enhance efficiency and safety. Railroad companies including CSX Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>), Norfolk Southern Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) and Union Pacific Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) may benefit from such improvement projects. 
Investors can also monitor the broader transportation sector through ETFs which track its performance including the iShares Trust iShares U.S. Transportation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IYT#BATS">IYT</a>) and the First Trust Nasdaq Transportation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXR#NASDAQ">FTXR</a>). 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image: Shutterstock&nbsp;

Travel

Movers

FTXR

iShares Dow Jones Transportation Average Index Fund

LCID

RIVN

TSLA

What Trump's DOT Pick Could Mean For EVs, Airlines, Railroad Stocks

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Markets

$BTC

$ETH

GOOG

MSFT

NVDA

Real Vision's Raoul Pal Says AI Open-Source Models Are So Big And Important That They Could Use Blockchain To Secure Their Code From Government Interference, Other AI

It is payable January 13, 2025 to shareholders of record December 30, 2024.

Dividends

McCormick Increases Quarterly Dividend From $0.42 To $0.45 Per Share On Its Common Stock

Real Vision's Raoul Pal Says Tesla's Robotaxis Could Likely Use Blockchain, Crypto Payments

Guidance

QFIN

Qifu Technology Expects Q4 Net Income Of RMB1.75B - RMB1.85B, Adj Net Income Of RMB1.80B -RMB1.90B, Representing 57% - 65% Year-on-year Growth

Real Vision's Raoul Pal Says The 'AI Layer' Of The Internet Is Coming; We Already Have Blockchain; Says This Is The 'Security Truth Layer,' Says We'll Need To Figure Out What Is Real Or Not For Everything

Qifu Technology Expects To See Relatively Stable Overall Risk Performance In The Coming Quarters As It Remains Vigilant In Risk Management Under Current Macro Environment

Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.83) by 18.07 percent. The company reported quarterly sales of $2.51 million which missed the analyst consensus estimate of $3.42 million by 26.71 percent. This is a 17.17 percent decrease over sales of $3.03 million the same period last year.

Earnings Misses

WKHS

Workhorse Gr Q3 2024 GAAP EPS $(0.98) Misses $(0.83) Estimate, Sales $2.51M Miss $3.42M Estimate

Real Vision's Raoul Pal Says Countries Will Use Crypto To Solve Interest Payments For National Debt

<ul>
<li>10-year PPA to deliver power from Argo and Brookfield's Smoky Mountain Hydro Facilities located in east Tennessee and western North Carolina</li>
<li>The hydro facilities will provide 377 MW of reliable, clean energy to meet demand growth in TVA's service territory</li>
<li>The PPA will support TVA's energy transition goal to achieve net-zero by 2050</li>
</ul>
Tennessee Valley Authority ("TVA") together with Argo Infrastructure Partners, LP ("Argo") and Brookfield Asset Management ("Brookfield") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/BAM#TSX">BAM</a>), with its listed affiliate Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEP#NYSE">BEP</a>, BEPC, TSX:<a class="ticker" href="https://www.benzinga.com/stock/BEP#TSX">BEP</a>, BEPC))) today announced the signing of a landmark 10-year power purchase agreement ("PPA") with power to be delivered by the Cheoah, Calderwood, Chilhowee and Santeetlah dams, together known as the Smoky Mountain Hydroelectric facilities ("Smoky"), which is jointly owned by Argo and Brookfield.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20241119725256/en/">https://www.businesswire.com/news/home/20241119725256/en/</a>
Smoky will begin delivering power through the PPA starting in 2025 and over the next decade, will supply more than 14 gigawatt hours of carbon-free energy to TVA customers, advancing TVA's transition towards its 2050 net-zero goal.
Smoky currently owns and operates a 377-megawatt portfolio of four hydroelectric power facilities across east Tennessee and western North Carolina. This portfolio generates an annual average of 1.4 million megawatt-hours of carbon-free energy—equivalent to approximately 1.1 million tons of CO2 emissions avoided each year.

Contracts

TSX:BAM

TSX:BEP

Tennessee Valley Authority Together With Argo Infrastructure Partners And Brookfield Asset Management, With Its Listed Affiliate Brookfield Renewable Announces The Signing Of A Landmark 10-Year PPA With Power To Be Delivered By The Smoky Mountain Hydroelectric Facilities, Which Is Jointly Owned By Argo And Brookfield

PHIO and MGRM among healthcare movers

VERI, CHEK and MESO are among pre market gainers

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd. has regained compliance with Nasdaq's public holders r...

Jin Medical Regains Nasdaq Compliance, Aims for Timely Filing

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical Technologies Ltd. faces scrutiny as its former auditor, DNTW Toronto LLP,...

Jin Medical Auditor Resigns Amid Dispute

WIRE, CUTR and USEG are among premarket  gainers

Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd. has successfully regained compliance with Nasdaq's fil...

Jin Medical Regains Nasdaq Compliance

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
June may not be the first month you consider when you plan to invest, but this isn&rsquo;t a month that should be overlooked. June is an ideal time to look for A-rated <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> to diversify your portfolio and lead to some potentially lucrative returns.



Penny stocks are shares of companies with stock valued under $5. It&rsquo;s appealing to investors since they can acquire a significant stake in a company with a small investment.



However, not all penny stocks are created equal, and the risks associated with them can be substantial. This is where A-rated penny stocks come into play.



A-rated penny stocks get their rankings from the Portfolio Grader, which assigns stocks a letter grade based on earnings performance, growth, analyst sentiment and buying momentum. By keeping your eye on A-rated penny stocks, you&rsquo;re assured of getting the best of these low-priced stocks and setting yourself up for a better overall return.



And with June being a popular month for companies to file earnings reports, investors are armed with new information about these companies&rsquo; performance and outlook.



There are seven A-rated penny stocks on today&rsquo;s list, and any of them would be a solid addition to a portfolio while mitigating the risks that are commonly associated with smaller companies.



<h2>Lexaria Bioscience (LEXX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div>Biotech companies can be challenging investments. Bringing a drug to market is no small feat, as it requires millions of dollars in research and development and multiple successful clinical trials before you can even consider seeking regulatory approval and achieve commercialization.



But Lexaria Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/lexx-stock-quote/">LEXX</a>) is an exception to the rule. The company is the creator of DehydraTECH, which is a drug delivery technology that improves the way active drugs enter the bloodstream.



DehydraTECH increases the absorption of the drug into a patient and helps the medication take effect faster. It also reduces the need for sugar-filled tablets, capsules and oral suspensions because it can mask the taste of medications.



Biotechs can incorporate the DehydraTECH platform into any of their oral medications to make them more effective and tolerable for patients.



Any drug delivery system that makes medications more effective and more tolerable to patients is going to be popular in the biotech field.



The DehydraTECH platform increases the absorption of the drug into a patient and helps the medication take effect faster. It also reduces the need for sugar-filled products because it can mask the taste of medications.



At the end of the <a href="https://ir.lexariabioscience.com/financial-information/financial-results">second quarter</a>, Lexaria was in a strong cash position, with $4.7 million on hand. Revenue in the quarter was only $145,000, but that is better than the $20,000 the company received in the second fiscal quarter of 2023. The company reported a loss of $668,000, but its losses are significantly dropping as the company edges toward profitability.



LEXX stock is up 130% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>JanOne (JAN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/ibio1600-300x169.jpg" alt="A scientist in medical gear peers through a microscope. IBIO stock"><div>Source: Shutterstock</div></div>JanOne (NASDAQ:<a href="https://investorplace.com/stock-quotes/jan-stock-quote/">JAN</a>) is yet another bioscience company. It is developing nonaddictive treatments for conditions that cause severe pain. Its work is dedicated to helping people manage their pain without getting hooked on a treatment and developing a dependency for a drug, such as opioids.



Its most promising drug in the pipeline is a treatment for peripheral artery disease. The drug candidate has successfully completed Phase 2A trials and is awaiting Phase 2B testing to treat the disease and the pain associated with peripheral artery disease.



In addition, JanOne has a wholly owned subsidiary called <a href="https://ir.janone.com/news-events/press-releases/detail/71/janones-subsidiary-alt5-reports-91-year-over-year">ALT5 Sigma</a>, which is a fintech company that provides next-generation blockchain powered technologies. The company processed $289 million in cryptocurrency transactions in April and May combined, which was a 91% increase from a year ago.



JanOne offers an interesting way to invest in biotech and also play the cryptocurrency space. The stock is up 333% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Ocugen (OCGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/ocgn1600-300x169.png" alt="Person holding smartphone with logo of US biopharmaceutical company Ocugen Inc. (OCGN) on screen in front of website. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>As a small biotech company headquartered in Pennsylvania, Ocugen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocgn-stock-quote/">OCGN</a>) is making its mark by developing and commercializing gene and cell therapies.



The company is also getting a nice boost on June 28 when it joins the Russell 3000 index, which measures the performance of the largest 3,000 U.S. companies. Its inclusion means that Ocugen stock will be included in exchange traded funds and products that track the Russell 3000.



Ocugen is working on a breakthrough modifier gene therapy product that might treat multiple retinal diseases with a single product. It also has several products in various phases of testing to treat eye diseases.



Ocugen showed $13.2 million in operating expenses for the first quarter and had $26.4 million of cash on hand. It posted a loss of 5 cents per share versus a loss of 8 cents per share a year ago.



Losses for small biotech companies are to be expected as it takes time and money to bring new therapies to market. But OCGN stock is one of the better penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> you can buy, as the stock is up 124% so far this year. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Kuke Music (KUKE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/02/music_1600-300x169.jpg" alt="A photo of someone writing out music on staff paper with guitars in the background."><div>Source: Kemedo/ShutterStock.com</div></div>Kuke Music (NYSE:<a href="https://investorplace.com/stock-quotes/kuke-stock-quote/">KUKE</a>) is a digital music company in China. The company is a leading provider of classical music licensing, subscriptions and smart education services in China.



The company leverages its diverse content offerings and experience in music education to provide smart music education products, including Kuke smart pianos and Kuke smart teaching systems.



The company is also the organizer of the Beijing Music Festival and is working to get into the AI music field through a <a href="https://finance.yahoo.com/news/kuke-jidou-join-forces-ai-122000084.html">partnership</a> with Shanghai Jidou Science and Technology, which will see Kuke lauch an AI music application through a digital automotive software platform that Jidou develops for more than a dozen automotive companies.



<a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&amp;ref=318325464&amp;type=HTML&amp;cdn=2794ad5ad1fb979a4aae2110f8badbd2&amp;formType=20-F&amp;dateFiled=2024-05-15&amp;cik=0001809158&amp;symbol=0001809158&amp;companyName=">Kuke and its subsidiaries</a> reported revenue in 2023 of 106.9 million Chinese yuan ($14.7 million) and a loss of 65.8 million Chinese yuan. But the AI music partnership provides a path for Kuke to turn those losses into profits.



KUKE stock is up 101% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Jin Medical (ZJYL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-single-300x169.jpg" alt="A close up photo of a penny. Penny Stocks to Buy"><div>Source: Shutterstock</div></div>Jin Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/zjyl-stock-quote/">ZJYL</a>) is another Chinese penny stock. The company makes and sells wheelchairs and other products for the elderly and those with disabilities.



The company operates two manufacturing plants with approximately 228,257 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. And it has relationships with more than 40 distributors in China and distributors in 20 other regions.



The majority of the company&rsquo;s wheelchair products, which includes 30 models, are sold in China and Japan.



As a Chinese company, Jin doesn&rsquo;t report its financials as often as those based in the U.S. But its <a href="https://ir.zhjmedical.com/se%D1%81filings">most current financial report</a> for the 2023 fiscal year (ending Sept. 30, 2023), included revenue of $19.8 million, up 3% from a year ago. 



Profits of $6.7 million were up 9.5% from the 2022 fiscal year, and total net income of $2.87 million was a 6.3% improvement from the previous year.



ZJYL stock, which had its initial public offering only a year ago, is having a rough 2024. The company performed a <a href="https://investorplace.com/2024/02/why-is-jin-medical-international-zjyl-stock-moving-today/">20-for-1 stock split,</a> which brought the stock price down from $217 to roughly $13.50. However, the stock has been slipping ever since, and is down in penny stock territory.



However, I&rsquo;m expecting a rebound based on the company&rsquo;s financials, and the stock currently maintains its &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Caravelle International (CACO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/tech-stocks-1600-300x169.png" alt="A hexagonal grid with different tech-related icons; Tech stocks illustration. Best Tech stocks. tech stocks trading at bargain prices"><div>Source: whiteMocca / Shutterstock</div></div>Caravelle International (NASDAQ:<a href="https://investorplace.com/stock-quotes/caco-stock-quote/">CACO</a>) is a global ocean technology company with headquarters in Singapore. The company has routes to 50 companies and serves more than 100 ports.



Caravelle&rsquo;s innovation lies in its work with shipping and lumber industries. The company invented a patent pending process called CO-Tech, which uses the heat from its ships&rsquo; exhaust to dry wood during transportation.



Caravelle says the process is an improvement from the lumber industry&rsquo;s practice of building and maintaining wood drying facilities and the energy required to heat the wood in those facilities.



Contrast this to the traditional wood desiccation process where lumber companies must build and maintain expensive wood drying facilities, spend money on energy to heat the wood, and emit massive amounts CO2.



The company already has a <a href="http://www.caravelleglobal.com/news-detail.html?newId=1783843089586188289">memorandum of understanding</a> with the government of Gabon to provide dried timber. If it can expand the business model to other governments, Caravelle may have a groundbreaking business on its hands.



CACO stock is up 63% this year, but is still priced at less than $1 per share. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Eco Wave Power (WAVE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1932365063-300x169.png" alt="Environmental protection, renewable, sustainable energy sources. Plant growing in the bulb concept. renewable energy stocks to buy"><div>Source: Proxima Studio / Shutterstock.com</div></div>Eco Wave Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/wave-stock-quote/">WAVE</a>) is a clean energy company that develops electricity from the power of ocean waves. 



If you&rsquo;ve ever been caught in a rough surf you know that even those waves can pack a punch, so imagine the power that an ocean wave can provide should we be able to harness that power and turn it into a clean source of electricity.



The company&rsquo;s floaters can be attached to human-made structures to simplify installation and maintenance. The floaters draw energy from incoming waves by converting the rising and falling motion into a clean energy generation process.



The company currently works with customers in Israel, Portugal, Los Angeles and Gibraltar, a British territory. 



While there was no revenue in the first quarter and the company sustained an operating loss of $659,000, management has high hopes that the company&rsquo;s clean energy solution will be a powerful argument for coastal cities.



WAVE stock is up 79% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/06/7-a-rated-penny-stocks-to-beat-june-gloom/">7 A-Rated Penny Stocks to Beat June Gloom</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 A-Rated Penny Stocks to Beat June Gloom

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd. has shown a robust financial performance in their late...

Jin Medical's Asset Growth Amidst Revenue Dip

Jin Medical International Ltd. (ZJYL) has released an update. Jin Medical International Ltd., a leader in Assistive Technologies manufacturing, has...

JinMed Expands with New High-Tech Facility

ABVC

ALLR

ANTE

APYX

ARGX

BPTH

BROG

CACO

CRDL

CZOO

DERM

DNUT

FLGC

HUBC

HUSA

INCR

INDO

KUKE

LEXX

LGVN

LOBO

LUXH

LXRX

MGRM

NKGN

NSYS

NUVB

OCGN

PHIO

PRAX

PROK

PRZO

PYXS

RENT

RVPH

STRO

TARA

TRML

WAVE

WINT

XFOR

ZJYL

Press Releases

JIN MEDICAL INTERNATIONAL LTD. Secures RMB66 Million in Orders for Innovative Micro-Hyperbaric Oxygen Chamber Equipment

JIN MEDICAL INTERNATIONAL LTD. Empowers "Lao Le Hui" Assisted Bathing Project with Portable Nano-thermal Therapy Bath

JIN MEDICAL INTERNATIONAL LTD. Enters into Memorandum of Understanding to Acquire Medical Equipment Sharing Platform

Opinion

Thinking about buying stock in Applied UV, Alphabet Inc, Alcoa, British American Tobacco, or Jin Medical International?

Comments

Jin Medical International

Interés en corto

Jin Medical International (NASDAQ:ZJYL) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL